

Press Release

ProStrakan Group plc

Peter Allen to Succeed Harry Stratford as Chairman of ProStrakan

Galashiels, Scotland, 30th October, 2007 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that its founder and Chairman, Harry Stratford OBE, has informed the Board of his intention to retire as Chairman at the end of 2007. Peter Allen, a Non-Executive Director since 2005, has accepted the Board's invitation to become Chairman from that point.

Harry co-founded ProStrakan in 1995 and served as its CEO until the appointment of Dr Wilson Totten as CEO in 2004, at which point Harry was appointed Chairman.

Wilson Totten said:

“As a founder of the company, Harry has played an immense role in building what is now one of Europe's fastest growing specialty pharma companies. His vision and tenacity were recently recognised by the award of an OBE for services to the Scottish Life Sciences industry. We all wish him great happiness, health and success in the future.

“I am particularly pleased to be able to welcome Peter as our new Chairman. Peter knows the company very well, and has already proved to be hugely influential in shaping the strategy of the Group as we build out through Europe and now into the USA.”

Peter Allen said:

“I am most flattered to be asked to take on the role of Chairman following Harry's retirement. He has created and shaped a very exciting business that is entering a key stage of its development as it moves towards profitability. I look forward to working with Wilson and his excellent team to continue the successful evolution of ProStrakan.”

Harry Stratford said:

“ProStrakan's entry into the US represents an inflection point for the Group and, for me, an appropriate time at which to hand over the reins. I am proud of what we have achieved with ProStrakan so far and I am delighted that Peter Allen is taking over as Chairman. His skills and knowledge should enable ProStrakan to continue its dynamic development.”

Further enquiries:

ProStrakan

Dr Wilson Totten, Chief Executive
Paul Garvey, Chief Financial Officer
Callum Spreng, Corporate Comms Director

Tel: +44 (0) 1896 664000

Financial Dynamics

David Yates/Ben Brewerton

Tel: +44 (0) 20 7831 3113

Trout Group (for US investors)

Gitanjali Jain Ogawa

Tel: +1 (646) 378-2949

Notes to Editors:

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, France, Germany, Spain and other EU countries. www.prostrakan.com

Harry Stratford OBE

Harry Stratford co-founded ProStrakan in 1995 and was CEO of the Company until his appointment as Executive Chairman in 2004. In 2006 he became Non-Executive Chairman of the Group. Harry is a founder and former CEO of Shire Pharmaceuticals. He has extensive experience of the pharmaceutical industry spanning over 30 years. He was awarded an OBE in the 2007 New Year's Honours List for his contribution to the Scottish Life Sciences industry.

Peter Allen

Peter Allen ACA was CFO and Deputy CEO of Celltech Group plc between 1992 and 2004. In addition to managing the company's flotation process in 1993, leading to a listing on the London Stock Exchange, Peter played a key role in several strategic acquisitions, including Chiroscience, Medeva and Oxford Glycosciences. In May 2004, Peter was a key participant in the sale of Celltech to UCB. Prior to this, he was Group Financial Controller of Associated British Ports Holdings plc and Financial Controller with L'Oreal (UK) Ltd. In April 2005, he was appointed CFO of Abacus Group plc, the quoted electronics distributor.